Skip to main content

ANI acquires 4 ANDAs from Oakrum Pharma

With the acquisition, ANI said it expects to launch four generic products in 2023.

ANI has purchased four abbreviated new drug applications from Oakrum Pharma, a privately owned biopharmaceutical company.

[Read more: ANI names new CEO]

“We are pleased to expand our generics product portfolio with the acquisition of four limited competition ANDAs. We expect to launch these products and see the value unlock in 2023,” said Nikhil Lalwani, president and CEO of ANI.

“This transaction bears further testament to ANI’s strength in business development and complements the significant investment and efforts of our internal research and development team to bring much-needed medicines to patients in need,” Lalwani said.

[Read more: FDA gives ANI green light for Cortrophin Gel]

Bourne Partners served as the exclusive financial advisor to Oakrum Pharma in this transaction.

This ad will auto-close in 10 seconds